Kanvas Biosciences Acquires Federation Bio Assets to Scale the Discovery, Development and Manufacturing of Microbiome-Based Therapeutics
As Federation Bio fades away, Kanvas Biosciences has snapped up two of the biotech’s assets as well as its microbial library and the company’s chief scientific officer Lee Swem, Ph.D., to lead program development.
Microbiome-focused Federation Bio has cut an undisclosed number of staff months after launching its first phase 1 trial.
The University of Texas MD Anderson Cancer Center has announced a strategic collaboration with Federation Bio for the development of a new microbiome treatment for immunotherapy-resistant cancer patients.
HOUSTON and SOUTH SAN FRANCISCO, Calif., Feb. 1, 2023 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Federation Bio, a biotechnology company pioneering bacterial cell therapies, today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy. The agreement pairs Federation Bio's proprietary ACT™ (anerobic co-culture technology) platform with the expertise and capabilities of MD Anderson's Platform for Innovative Microbiome and Translational Research (PRIME-TR).
SOUTH SAN FRANCISCO, Calif., Dec. 8, 2022 /PRNewswire/ -- Federation Bio, a biotechnology company pioneering bacterial cell therapies, today announced that investigators have administered the first dose in a Phase 1 clinical study evaluating the company's lead therapeutic candidate, FB-001, for the treatment of enteric hyperoxaluria.